Liver-Kidney Transplantation to Cure Atypical Hemolytic Uremic Syndrome
Open accessThe DOI matches its Crossref record.
Abstract
Atypical hemolytic uremic syndrome is often associated with mutations in genes encoding complement regulatory proteins and secondary disorders of complement regulation. Progression to kidney failure and recurrence with graft loss after kidney transplantation are frequent. The most common mutation is in the gene encoding complement factor H. Combined liver-kidney transplantation may correct this complement abnormality and prevent recurrence when the defect involves genes encoding circulating proteins that are synthesized in the liver, such as factor H or I. Good outcomes have been reported when surgery is associated with intensified plasma therapy. A consensus conference to establish treatment guidelines for atypical hemolytic uremic syndrome was held in Bergamo in December 2007. The recommendations in this article are the result of combined clinical experience, shared research expertise, and a review of the literature and registry information. This statement defines groups in which isolated kidney transplantation is extremely unlikely to be successful and a combined liver-kidney transplant is recommended and also defines those for whom kidney transplant remains a viable option. Although combined liver-kidney or isolated liver transplantation is the preferred therapeutic option in many cases, the gravity of risk associated with the procedure has not been eliminated completely, and assessment of risk and benefit requires careful and individual attention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208981 · Cited by 1,586
Self-citationAtypical Hemolytic–Uremic Syndrome
Noris, M., & Remuzzi, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902814 · Cited by 1,338
Self-citationNoris, M., Caprioli, J., Bresin, E., Mossali, C., Pianetti, G., Gamba, S., Daina, E., Fenili, C., Castelletti, F., Sorosina, A., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02210310 · Cited by 1,042
Self-citationSchwartz, J., Padmanabhan, A., Aqui, N., Balogun, R. A., Connelly‐Smith, L., Delaney, M., Dunbar, N. M., Witt, V., Wu, Y., & Shaz, B. H. (2016) · Journal of Clinical Apheresis · doi:10.1002/jca.21470 · Cited by 793
Chadban, S. J., Ahn, C., Axelrod, D. A., Foster, B. J., Kasiske, B. L., Kher, V., Kumar, D., Oberbauer, R., Pascual, J., Pilmore, H. L., et al. (2020) · Transplantation · doi:10.1097/tp.0000000000003136 · Cited by 738
Atypical hemolytic uremic syndrome
Loirat, C., & Frémeaux-Bacchi, V. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-60 · Cited by 669
Schwartz, J., Winters, J. L., Padmanabhan, A., Balogun, R. A., Delaney, M., Linenberger, M. L., Szczepiorkowski, Z. M., Williams, M. E., Wu, Y., & Shaz, B. H. (2013) · Journal of Clinical Apheresis · doi:10.1002/jca.21276 · Cited by 603
International, F. H., Loirat, C., Fakhouri, F., Ariceta, G., Besbas, N., Bitzan, M., Bjerre, A., Coppo, R., Emma, F., Johnson, S., et al. (2016) · Pediatric Nephrology · doi:10.1007/s00467-015-3076-8 · Cited by 596
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
on behalf of the French Study Group for aHUS/C3G, Zuber, J., Fakhouri, F., Roumenina, L. T., Loirat, C., & Frémeaux-Bacchi, V. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.214 · Cited by 496
Atypical Hemolytic Uremic Syndrome
Kavanagh, D., Goodship, T. H., & Richards, A. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.08.003 · Cited by 348
Taylor, C. M., Machin, S., Wigmore, S. J., Goodship, T. H. J., & on behalf of a working party from the Renal Association, T. B. C. F. S. I. H. A. T. B. T. S. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07916.x · Cited by 277
Campistol, J. M., Arias, M., Ariceta, G., Blasco, M., Espinosa, L., Espinosa, M., Grinyó, J. M., Macía, M., Mendizábal, S., Praga, M., et al. (2015) · Nefrología · doi:10.1016/j.nefro.2015.07.005 · Cited by 272
Le Quintrec, M., Zuber, J., Moulin, B., Kamar, N., Jablonski, M., Lionet, A., Chatelet, V., Mousson, C., Mourad, G., Bridoux, F., et al. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12077 · Cited by 268
A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
Rathbone, J., Kaltenthaler, E., Richards, A., Tappenden, P., Bessey, A., & Cantrell, A. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003573 · Cited by 110
Metadata
- Authors
- Saland, J. M., Ruggenenti, P., & Remuzzi, G.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2009-05
- Volume
- 20
- Issue
- 5
- Pages
- 940-949
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2159597368
- Cited by
- 165
- References
- 0
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.